193 related articles for article (PubMed ID: 22316571)
1. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
Byakika-Kibwika P; Lamorde M; Okaba-Kayom V; Mayanja-Kizza H; Katabira E; Hanpithakpong W; Pakker N; Dorlo TP; Tarning J; Lindegardh N; de Vries PJ; Back D; Khoo S; Merry C
J Antimicrob Chemother; 2012 May; 67(5):1217-23. PubMed ID: 22316571
[TBL] [Abstract][Full Text] [Related]
2. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Byakika-Kibwika P; Lamorde M; Mayito J; Nabukeera L; Namakula R; Mayanja-Kizza H; Katabira E; Ntale M; Pakker N; Ryan M; Hanpithakpong W; Tarning J; Lindegardh N; de Vries PJ; Khoo S; Back D; Merry C
J Antimicrob Chemother; 2012 Sep; 67(9):2213-21. PubMed ID: 22687893
[TBL] [Abstract][Full Text] [Related]
3. The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
Kredo T; Mauff K; Workman L; Van der Walt JS; Wiesner L; Smith PJ; Maartens G; Cohen K; Barnes KI
BMC Infect Dis; 2016 Jan; 16():30. PubMed ID: 26818566
[TBL] [Abstract][Full Text] [Related]
4. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
Kredo T; Mauff K; Van der Walt JS; Wiesner L; Maartens G; Cohen K; Smith P; Barnes KI
Antimicrob Agents Chemother; 2011 Dec; 55(12):5616-23. PubMed ID: 21947399
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
German P; Parikh S; Lawrence J; Dorsey G; Rosenthal PJ; Havlir D; Charlebois E; Hanpithakpong W; Lindegardh N; Aweeka FT
J Acquir Immune Defic Syndr; 2009 Aug; 51(4):424-9. PubMed ID: 19506482
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
[TBL] [Abstract][Full Text] [Related]
7. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Hughes E; Mwebaza N; Huang L; Kajubi R; Nguyen V; Nyunt MM; Orukan F; Mwima MW; Parikh S; Aweeka F
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):140-147. PubMed ID: 31929402
[TBL] [Abstract][Full Text] [Related]
8. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
Hoglund RM; Byakika-Kibwika P; Lamorde M; Merry C; Ashton M; Hanpithakpong W; Day NP; White NJ; Äbelö A; Tarning J
Br J Clin Pharmacol; 2015 Apr; 79(4):636-49. PubMed ID: 25297720
[TBL] [Abstract][Full Text] [Related]
9. An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.
Francis J; Barnes KI; Workman L; Kredo T; Vestergaard LS; Hoglund RM; Byakika-Kibwika P; Lamorde M; Walimbwa SI; Chijioke-Nwauche I; Sutherland CJ; Merry C; Scarsi KK; Nyagonde N; Lemnge MM; Khoo SH; Bygbjerg IC; Parikh S; Aweeka FT; Tarning J; Denti P
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071050
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT
Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
12. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy.
Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465
[TBL] [Abstract][Full Text] [Related]
13. Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
Usman SO; Oreagba IA; Akinyede AA; Agbaje EO; Akinleye MO; Onwujuobi AG; Ken-Owotor C; Adeuja O; Ogunfowokan T; Kogbe S; Owolabi ET; Adeniji H; Busari AW; Hassan OO; Abideen G; Akanmu AS
J Pharmacol Sci; 2020 Nov; 144(3):95-101. PubMed ID: 32921396
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals.
Kiang TK; Wilby KJ; Ensom MH
Clin Pharmacokinet; 2014 Feb; 53(2):141-53. PubMed ID: 24158666
[TBL] [Abstract][Full Text] [Related]
15. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
[TBL] [Abstract][Full Text] [Related]
16. Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Kay K; Goodwin J; Ehrlich H; Ou J; Freeman T; Wang K; Li F; Wade M; French J; Huang L; Aweeka F; Mwebaza N; Kajubi R; Riggs M; Ruiz-Garcia A; Parikh S
Clin Pharmacol Ther; 2023 Mar; 113(3):660-669. PubMed ID: 36260349
[TBL] [Abstract][Full Text] [Related]
17. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
Huang L; Carey V; Lindsey JC; Marzan F; Gingrich D; Graham B; Barlow-Mosha L; Ssemambo PK; Kamthunzi P; Nachman S; Parikh S; Aweeka FT;
PLoS One; 2017; 12(10):e0186589. PubMed ID: 29065172
[TBL] [Abstract][Full Text] [Related]
18. Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection.
Adegbola A; Abutaima R; Olagunju A; Ijarotimi O; Siccardi M; Owen A; Soyinka J; Bolaji O
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082286
[TBL] [Abstract][Full Text] [Related]
19. Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment.
Lamorde M; Byakika-Kibwika P; Mayito J; Nabukeera L; Ryan M; Hanpithakpong W; Lefèvre G; Back DJ; Khoo SH; Merry C
AIDS; 2013 Mar; 27(6):961-965. PubMed ID: 23698061
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
Abdullahi ST; Olagunju A; Soyinka JO; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Owen A; Khoo S
Br J Clin Pharmacol; 2019 Mar; 85(3):540-550. PubMed ID: 30471138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]